{"component": "clause", "props": {"groups": [{"snippet": "Phase III shall consist of the monitoring of the construction of the Project to ensure that the work is installed in accordance with the requirements of the Construction Documents and all applicable codes and regulations. This phase includes monitoring and management, as appropriate, of all change orders and pay requests, and the implementation of the building assurance program established in the Using Agency\u2019s Program. Major Deliverables: Review/recommendation on GMP Change Order Review/recommendation on Change Orders Review/recommendation on DP invoices Review/recommendation on CM/GC Pay Applications Periodic Construction IAW Design Reviews Periodic Cost Analysis Updates Professional Services: Engineering and design review services Budget and costing services Project management services", "samples": [{"hash": "dffZCXNBcAv", "uri": "/contracts/dffZCXNBcAv#phase-iii", "label": "Program Manager Contract", "score": 34.0079707409, "published": true}, {"hash": "2dt0EMbzuWk", "uri": "/contracts/2dt0EMbzuWk#phase-iii", "label": "Program Manager Contract", "score": 31.3581989233, "published": true}, {"hash": "dcM8GNbVkFT", "uri": "/contracts/dcM8GNbVkFT#phase-iii", "label": "Program Manager Contract", "score": 31.2979768365, "published": true}], "snippet_links": [{"key": "consist-of", "type": "clause", "offset": [16, 26]}, {"key": "construction-of-the-project", "type": "clause", "offset": [49, 76]}, {"key": "to-ensure", "type": "clause", "offset": [77, 86]}, {"key": "the-work", "type": "definition", "offset": [92, 100]}, {"key": "in-accordance-with", "type": "definition", "offset": [114, 132]}, {"key": "the-construction-documents", "type": "clause", "offset": [153, 179]}, {"key": "codes-and-regulations", "type": "clause", "offset": [199, 220]}, {"key": "monitoring-and-management", "type": "clause", "offset": [242, 267]}, {"key": "change-orders", "type": "definition", "offset": [292, 305]}, {"key": "pay-requests", "type": "clause", "offset": [310, 322]}, {"key": "the-building", "type": "definition", "offset": [350, 362]}, {"key": "program-established", "type": "clause", "offset": [373, 392]}, {"key": "using-agency", "type": "definition", "offset": [400, 412]}, {"key": "major-deliverables", "type": "clause", "offset": [424, 442]}, {"key": "change-order-review", "type": "clause", "offset": [473, 492]}, {"key": "pay-applications", "type": "clause", "offset": [593, 609]}, {"key": "design-reviews", "type": "clause", "offset": [636, 650]}, {"key": "cost-analysis", "type": "definition", "offset": [660, 673]}, {"key": "professional-services", "type": "definition", "offset": [682, 703]}, {"key": "engineering-and-design", "type": "clause", "offset": [705, 727]}, {"key": "services-budget", "type": "definition", "offset": [735, 750]}, {"key": "project-management-services", "type": "definition", "offset": [772, 799]}], "size": 9, "hash": "e4a9b951745b971b8140d4b29c80ba8b", "id": 1}, {"snippet": "The Parties pledge as confidence building measures that they shall:\na. within 120 days after the Transfer of Authority withdraw all heavy weapons and Forces to cantonment/barracks areas or other locations as designated by the IFOR Commander. \u201cHeavy weapons\u201d refers to all tanks and armored vehicles, all artillery 75 mm and above, all mortars 81 mm and above, and all anti-aircraft weapons 20 mm and above. This movement of these Forces to cantonment/barracks areas is intended to enhance mutual confidence by the Parties in the success of this Annex and help the overall cause of peace in Bosnia and Herzegovina.", "samples": [{"hash": "5354i4id4ci", "uri": "/contracts/5354i4id4ci#phase-iii", "label": "Agreement on the Military Aspects of the Peace Settlement", "score": 34.2548945848, "published": true}, {"hash": "1nJLigHJDhc", "uri": "/contracts/1nJLigHJDhc#phase-iii", "label": "General Framework Agreement", "score": 34.0192799588, "published": true}, {"hash": "fr82Mj6aOso", "uri": "/contracts/fr82Mj6aOso#phase-iii", "label": "General Framework Agreement", "score": 33.9101517681, "published": true}], "snippet_links": [{"key": "confidence-building-measures", "type": "clause", "offset": [22, 50]}, {"key": "days-after", "type": "definition", "offset": [82, 92]}, {"key": "transfer-of-authority", "type": "clause", "offset": [97, 118]}, {"key": "heavy-weapons", "type": "definition", "offset": [132, 145]}, {"key": "other-locations", "type": "clause", "offset": [189, 204]}, {"key": "as-designated", "type": "definition", "offset": [205, 218]}, {"key": "by-the-parties", "type": "clause", "offset": [507, 521]}, {"key": "this-annex", "type": "clause", "offset": [540, 550]}, {"key": "bosnia-and-herzegovina", "type": "clause", "offset": [590, 612]}], "size": 6, "hash": "c2fb411a39cefe5887c4da4f8e9be4c1", "id": 2}, {"snippet": "If the Contractor elects to enter Phase III of the Exploration Period, then during such Phase III the Contractor shall drill one (1) well.", "samples": [{"hash": "juZWcc4J48k", "uri": "/contracts/juZWcc4J48k#phase-iii", "label": "Production Sharing Contract", "score": 30.340862423, "published": true}, {"hash": "dXm29FtuJME", "uri": "/contracts/dXm29FtuJME#phase-iii", "label": "Production Sharing Contract", "score": 29.2285269459, "published": true}, {"hash": "f9rkWYu5xPg", "uri": "/contracts/f9rkWYu5xPg#phase-iii", "label": "Production Sharing Contract (Kosmos Energy Ltd.)", "score": 27.3449691992, "published": true}], "snippet_links": [{"key": "if-the-contractor", "type": "clause", "offset": [0, 17]}, {"key": "to-enter", "type": "definition", "offset": [25, 33]}, {"key": "exploration-period", "type": "definition", "offset": [51, 69]}, {"key": "the-contractor-shall", "type": "clause", "offset": [98, 118]}], "size": 4, "hash": "5a973abc219216a6cf1de67464b34e46", "id": 3}, {"snippet": "The term \u201cPhase III\u201d shall mean an expanded human clinical study in any country on a sufficient number of subjects that is designated to establish that a Product is safe and efficacious for its intended use, and to determine warnings, precautions, and adverse reactions, if any, that are associated with Product in the dosage range to be prescribed, which trial is designed to result in regulatory approval of such Product, including all tests, studies, or a similar clinical study prescribed by the regulatory authorities, from time to time, pursuant to applicable law or otherwise including for example trials referred to in 21 C.F.R. 312.21(c).", "samples": [{"hash": "bFUOI5Uw2hr", "uri": "/contracts/bFUOI5Uw2hr#phase-iii", "label": "License Agreement (Neumora Therapeutics, Inc.)", "score": 34.6454483231, "published": true}, {"hash": "8O9Rhnet7c9", "uri": "/contracts/8O9Rhnet7c9#phase-iii", "label": "License Agreement (Neumora Therapeutics, Inc.)", "score": 33.1204654346, "published": true}, {"hash": "38LBq1c4GCv", "uri": "/contracts/38LBq1c4GCv#phase-iii", "label": "License Agreement (Neumora Therapeutics, Inc.)", "score": 32.9753593429, "published": true}], "snippet_links": [{"key": "the-term", "type": "clause", "offset": [0, 8]}, {"key": "clinical-study", "type": "clause", "offset": [50, 64]}, {"key": "number-of-subjects", "type": "clause", "offset": [96, 114]}, {"key": "to-establish", "type": "clause", "offset": [134, 146]}, {"key": "intended-use", "type": "clause", "offset": [194, 206]}, {"key": "to-determine", "type": "definition", "offset": [212, 224]}, {"key": "adverse-reactions", "type": "definition", "offset": [252, 269]}, {"key": "associated-with", "type": "definition", "offset": [288, 303]}, {"key": "approval-of", "type": "clause", "offset": [398, 409]}, {"key": "regulatory-authorities", "type": "definition", "offset": [500, 522]}, {"key": "from-time-to-time", "type": "clause", "offset": [524, 541]}, {"key": "applicable-law", "type": "clause", "offset": [555, 569]}, {"key": "for-example", "type": "definition", "offset": [593, 604]}], "size": 3, "hash": "3589278f51c9ad91d4f2f5bcb6720214", "id": 4}, {"snippet": "If GEM elects to participate in Phase III, it shall pay to Ohio Cumberland, within ten (10) days of receipt by Ohio Cumberland of GEM\u2019s written election to participate, the sum of Five Hundred Thousand And No/100 Dollars ($500,000.00) as the third and final payment of the initial prospect costs (\u201cThird Prospect Payment\u201d). Said payment shall be via wire transfer of immediately available funds to the banking coordinates identified, in writing by Ohio Cumberland. Subject to Section 9.16, GEM\u2019s failure to pay timely shall cause this Agreement to terminate and become null and void as between the Parties.\n(a) Notwithstanding the operator replacement provisions in the Cumberland Prospect Operating Agreement, GEM shall have the option at any time, after GEM makes the Third Prospect Payment and after consultation with Ohio Cumberland, to become the contract operator or to appoint a designee as contract operator. For the purposes of this Agreement the term \u201cContract Operator\u201d shall mean GEM, if it elects to become the contract operator or its designee contract operator and shall not be interchanged with the term \u201coperator\u201d as hereinafter defined. If GEM elects to become the Contract Operator, then Ohio Cumberland and the Operator shall be obligated to take all reasonably necessary actions to make GEM or a designee the contract operator for the Cumberland Prospect Area for the purposes of this Agreement; such contract operating agreement shall be consistent with industry standards, have a term of one year (and may be renewable, unless terminated earlier by Ohio Cumberland pursuant to Section 3.4(c) hereinbelow), provide that all Overhead charges under the Cumberland Prospect Operating Agreement shall be paid to the Contract Operator, but shall provide for distribution of production revenues by the Contract Operator only if the first purchaser of production who is not a Party, refuses to distribute directly to the Parties. If GEM elects to become the Contract Operator or elects a designee to be the Contract Operator, neither GEM nor its designee shall in any manner change or modify the scheduling or implementation of the Phase II Report or change or modify any AFE previously submitted to GEM pursuant to the terms of this Agreement.\n(b) Within ninety (90) days of Ohio Cumberland\u2019s receipt of the Third Prospect Payment, the Operator shall commence operations for Phase III, in accordance with the Phase II Report. The Phase III operations will begin the development drilling of the Cumberland Prospect Area. Phase III will end at the point in time when GEM has met the Carried Interest Amount as defined in Section 3.5 below.\n(c) In addition to the payment of the Third Prospect Payment, GEM shall pay all of the costs for all operations to be conducted in Phase III until GEM has paid the Carried Interest Amount. Subject to the provisions of Section 3.7, GEM shall pay 100% of the actual costs incurred for Phase III until GEM has paid the Carried Interest Amount. Within ten (10) days after Ohio Cumberland\u2019s receipt of the Third Prospect Payment, the Operator shall submit to GEM an AFE for 100% of the estimated costs for all operations to be conducted pursuant to the Phase II Report for the first calendar quarter. GEM shall pay to the Operator the total AFE amount within thirty (30) days from its receipt of the AFE and shall contemporaneously deliver a fully executed AFE. Thereafter the Operator shall submit to GEM at least thirty (30) days prior to the next calendar quarter an AFE for 100% of the estimated costs for all operations to be conducted pursuant to the Phase II Report for the next calendar quarter. GEM shall pay to the Operator the total AFE amount within thirty (30) days from its receipt of the AFE and shall deliver an executed AFE with its payment. The Operator shall continue to submit AFE\u2019s on a quarterly basis until such time as the Carried Interest Amount has been reached. Once the Carried Interest Amount is met, then Phase III shall end. Subject to Section 9.16 of this Agreement, failure by GEM to timely pay the full amount of each AFE submitted by the Operator for the Phase III costs shall cause the Agreement to terminate and become null and void as between the Parties. GEM shall only be entitled to an assignment of a forty (40) acre production unit, as to all depths, surrounding each well drilled. Said forty (40) acre production unit shall be the closest quarter (1/4) quarter (1/4) section of land surrounding each such well.", "samples": [{"hash": "jWBa9IIHr9Q", "uri": "/contracts/jWBa9IIHr9Q#phase-iii", "label": "Exploration and Development Agreement (Harken Energy Corp)", "score": 21.0, "published": true}], "snippet_links": [{"key": "participate-in", "type": "definition", "offset": [17, 31]}, {"key": "pay-to", "type": "definition", "offset": [52, 58]}, {"key": "days-of-receipt", "type": "clause", "offset": [92, 107]}, {"key": "election-to-participate", "type": "definition", "offset": [144, 167]}, {"key": "sum-of", "type": "clause", "offset": [173, 179]}, {"key": "payment-of-the", "type": "clause", "offset": [258, 272]}, {"key": "transfer-of", "type": "definition", "offset": [355, 366]}, {"key": "immediately-available-funds", "type": "clause", "offset": [367, 394]}, {"key": "in-writing", "type": "clause", "offset": [434, 444]}, {"key": "subject-to-section", "type": "clause", "offset": [465, 483]}, {"key": "failure-to-pay-timely", "type": "clause", "offset": [496, 517]}, {"key": "agreement-to-terminate", "type": "clause", "offset": [535, 557]}, {"key": "null-and-void", "type": "definition", "offset": [569, 582]}, {"key": "between-the-parties", "type": "clause", "offset": [586, 605]}, {"key": "notwithstanding-the", "type": "definition", "offset": [611, 630]}, {"key": "replacement-provisions", "type": "clause", "offset": [640, 662]}, {"key": "the-option", "type": "clause", "offset": [726, 736]}, {"key": "at-any-time", "type": "clause", "offset": [737, 748]}, {"key": "after-consultation-with", "type": "clause", "offset": [797, 820]}, {"key": "contract-operator", "type": "definition", "offset": [852, 869]}, {"key": "for-the-purposes-of-this-agreement", "type": "clause", "offset": [917, 951]}, {"key": "necessary-actions", "type": "clause", "offset": [1282, 1299]}, {"key": "prospect-area", "type": "definition", "offset": [1367, 1380]}, {"key": "contract-operating-agreement", "type": "definition", "offset": [1422, 1450]}, {"key": "consistent-with", "type": "clause", "offset": [1460, 1475]}, {"key": "industry-standards", "type": "definition", "offset": [1476, 1494]}, {"key": "term-of", "type": "clause", "offset": [1503, 1510]}, {"key": "one-year", "type": "clause", "offset": [1511, 1519]}, {"key": "pursuant-to-section", "type": "definition", "offset": [1588, 1607]}, {"key": "overhead-charges", "type": "clause", "offset": [1646, 1662]}, {"key": "production-revenues", "type": "clause", "offset": [1791, 1810]}, {"key": "first-purchaser", "type": "definition", "offset": [1848, 1863]}, {"key": "a-party", "type": "clause", "offset": [1889, 1896]}, {"key": "to-distribute", "type": "definition", "offset": [1906, 1919]}, {"key": "phase-ii-report", "type": "definition", "offset": [2147, 2162]}, {"key": "terms-of-this-agreement", "type": "clause", "offset": [2235, 2258]}, {"key": "receipt-of", "type": "clause", "offset": [2309, 2319]}, {"key": "commence-operations", "type": "definition", "offset": [2367, 2386]}, {"key": "for-phase", "type": "clause", "offset": [2387, 2396]}, {"key": "in-accordance-with", "type": "definition", "offset": [2402, 2420]}, {"key": "development-drilling", "type": "definition", "offset": [2482, 2502]}, {"key": "in-time", "type": "definition", "offset": [2568, 2575]}, {"key": "interest-amount", "type": "clause", "offset": [2605, 2620]}, {"key": "section-35", "type": "clause", "offset": [2635, 2646]}, {"key": "the-payment", "type": "clause", "offset": [2673, 2684]}, {"key": "section-37", "type": "clause", "offset": [2872, 2883]}, {"key": "actual-costs-incurred", "type": "clause", "offset": [2911, 2932]}, {"key": "days-after", "type": "definition", "offset": [3011, 3021]}, {"key": "submit-to", "type": "clause", "offset": [3098, 3107]}, {"key": "estimated-costs", "type": "definition", "offset": [3135, 3150]}, {"key": "calendar-quarter", "type": "clause", "offset": [3232, 3248]}, {"key": "the-total", "type": "clause", "offset": [3280, 3289]}, {"key": "within-thirty", "type": "clause", "offset": [3301, 3314]}, {"key": "fully-executed", "type": "definition", "offset": [3391, 3405]}, {"key": "prior-to-the", "type": "clause", "offset": [3481, 3493]}, {"key": "to-submit", "type": "definition", "offset": [3836, 3845]}, {"key": "on-a-quarterly-basis", "type": "definition", "offset": [3852, 3872]}, {"key": "failure-by", "type": "clause", "offset": [4048, 4058]}, {"key": "by-the-operator", "type": "clause", "offset": [4115, 4130]}, {"key": "the-agreement", "type": "clause", "offset": [4167, 4180]}, {"key": "assignment-of-a", "type": "clause", "offset": [4276, 4291]}, {"key": "production-unit", "type": "definition", "offset": [4308, 4323]}, {"key": "section-of-land", "type": "definition", "offset": [4460, 4475]}], "size": 3, "hash": "c9ab24da83e2dc1d6f264343472716ee", "id": 5}, {"snippet": "Tenant shall pay Base Rent for Phase III Expansion Premises in accordance with the following: 3/1/13 - 2/28/14 $ 197,894.55 $ 16,491.21 3/1/14 - 2/28/15 $ 202,987.05 $ 16,915.59 3/1/15 - 2/28/16 $ 208,079.55 $ 17,339.96 3/1/16 - 2/28/17 $ 213,172.05 $ 17,764.34 3/1/17 - 2/28/18 $ 218,264.55 $ 18,188.71 3/1/18 - 4/30/19 $ 223,357.05 $ 18,613.09 Anything to the contrary notwithstanding, Tenant shall not be required to pay Base Rent or Additional Rent for the first eight (8) months of the Term for Phase III Expansion Premises.", "samples": [{"hash": "7DEvh2fQwal", "uri": "/contracts/7DEvh2fQwal#phase-iii", "label": "Lease (Paylocity Holding Corp)", "score": 23.0793976728, "published": true}, {"hash": "fLGpSyyMwA", "uri": "/contracts/fLGpSyyMwA#phase-iii", "label": "Lease (Paylocity Holding Corp)", "score": 22.9288158795, "published": true}], "snippet_links": [{"key": "tenant-shall", "type": "clause", "offset": [0, 12]}, {"key": "base-rent", "type": "clause", "offset": [17, 26]}, {"key": "in-accordance-with", "type": "definition", "offset": [60, 78]}, {"key": "to-pay", "type": "clause", "offset": [417, 423]}, {"key": "additional-rent", "type": "definition", "offset": [437, 452]}, {"key": "the-term", "type": "clause", "offset": [487, 495]}], "size": 2, "hash": "137e6d802ebb97598aabfe5469dee955", "id": 6}, {"snippet": "Within thirty (30) days following the date on which Celltech first administers any Licensed Product to a human subject in a Phase III Clinical Trial on a Licensed Product, Celltech shall pay NeoGenesis [*]. \"Phase III Clinical Trial\" shall mean any clinical study in any Major Country of a Licensed Product, the primary purpose of which is evaluating statistical significance of the safety and efficacy of the Licensed Product in patients with the disease target being studied as required by the relevant Regulatory Authority to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.", "samples": [{"hash": "lGTckjGyuzW", "uri": "/contracts/lGTckjGyuzW#phase-iii", "label": "Research, License and Collaboration Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}, {"hash": "2gz1JZrHrUr", "uri": "/contracts/2gz1JZrHrUr#phase-iii", "label": "Research, License and Collaboration Agreement (Neogenesis Pharmaceuticals Inc)", "score": 18.0, "published": true}], "snippet_links": [{"key": "within-thirty", "type": "clause", "offset": [0, 13]}, {"key": "following-the", "type": "definition", "offset": [24, 37]}, {"key": "licensed-product", "type": "clause", "offset": [83, 99]}, {"key": "human-subject", "type": "definition", "offset": [105, 118]}, {"key": "phase-iii-clinical-trial", "type": "definition", "offset": [124, 148]}, {"key": "clinical-study", "type": "clause", "offset": [249, 263]}, {"key": "major-country", "type": "definition", "offset": [271, 284]}, {"key": "purpose-of", "type": "clause", "offset": [320, 330]}, {"key": "statistical-significance", "type": "definition", "offset": [351, 375]}, {"key": "safety-and-efficacy", "type": "clause", "offset": [383, 402]}, {"key": "as-required-by", "type": "clause", "offset": [477, 491]}, {"key": "authority-to", "type": "clause", "offset": [516, 528]}, {"key": "overall-benefit", "type": "clause", "offset": [542, 557]}, {"key": "relationship-of-the", "type": "clause", "offset": [563, 582]}, {"key": "to-provide", "type": "definition", "offset": [592, 602]}], "size": 2, "hash": "b26de573d8f61518a07aa54fd5b74af8", "id": 7}, {"snippet": "The collective bargaining agreement (CBA) process begins. Initially affected employees and/or secondarily affected employees may then exercise their rights under the CBA. The CBA process ends when either (1) the affected employee(s) has a comparable job; or (2) the affected employee(s) choose to waive further contractual displacement rights and enter Phase III.", "samples": [{"hash": "eiVJcUbz1zq", "uri": "/contracts/eiVJcUbz1zq#phase-iii", "label": "Bargaining Unit Contract", "score": 26.2854209446, "published": true}, {"hash": "daLiocOpn8e", "uri": "/contracts/daLiocOpn8e#phase-iii", "label": "Bargaining Unit Contract", "score": 25.3983572895, "published": true}], "snippet_links": [{"key": "collective-bargaining-agreement", "type": "definition", "offset": [4, 35]}, {"key": "affected-employees", "type": "definition", "offset": [68, 86]}, {"key": "employees-may", "type": "clause", "offset": [115, 128]}, {"key": "comparable-job", "type": "clause", "offset": [239, 253]}, {"key": "to-waive", "type": "clause", "offset": [294, 302]}, {"key": "displacement-rights", "type": "definition", "offset": [323, 342]}], "size": 2, "hash": "8dbf96ada2199b263798118ee3226942", "id": 8}, {"snippet": "As used herein, \u201cPhase III\u201d shall mean Verification of Design, including acceptance testing of LSR Instrument Prototypes.", "samples": [{"hash": "cyjVMo0H2U4", "uri": "/contracts/cyjVMo0H2U4#phase-iii", "label": "Development Services and Equity Participation Agreement (Quanterix Corp)", "score": 28.8548939083, "published": true}, {"hash": "eOizVAzVQoB", "uri": "/contracts/eOizVAzVQoB#phase-iii", "label": "Development Services and Equity Participation Agreement (Quanterix Corp)", "score": 28.6249144422, "published": true}], "snippet_links": [{"key": "acceptance-testing", "type": "definition", "offset": [73, 91]}], "size": 2, "hash": "a9999e23999191a2676072fe161d9130", "id": 9}, {"snippet": "Upon Commencement of the first Phase III trial in the United States, Europe or Japan by SuperGen for the first therapeutic clinical candidate covered under the Licensed Patents, not necessarily restricted to cancer indications, SuperGen will pay to Licensor the sum of one million five hundred thousand U.S. dollars ($1,500,000) in cash or SuperGen stock along with piggyback registration rights therefor. Upon Commencement of Phase III trial in the United States, Europe or Japan by SuperGen for subsequent therapeutic clinical candidates covered under the Licensed Patents, SuperGen will pay to Licensor the sum of seven hundred and fifty thousand U.S. dollars ($750,000) in cash or SuperGen stock along with piggyback registration rights therefor. In the event SuperGen undertakes a Phase II/III clinical trial , then Commencement of such Phase II/III trial, and not of a Phase III trial, shall trigger the payment described in this section. A Phase II/III trial is defined as a pivotal study in which a therapeutic clinical candidate is being tested in humans for safety and efficacy in an expanded patient population at geographically dispersed clinical sites on the basis of which SuperGen will seek regulatory approval in lieu of a Phase III trial. Determination that a clinical trial is a Phase II/III shall be exclusively by SuperGen after conferring with the appropriate regulatory authority. Commencement (\u201cCommencement\u201d) is defined as the dosing of the first patient under a protocol involving a therapeutic clinical candidate covered under the Licensed Patents, not necessarily restricted to cancer indications.", "samples": [{"hash": "6UqItMUYric", "uri": "/contracts/6UqItMUYric#phase-iii", "label": "License Agreement (Supergen Inc)", "score": 21.0, "published": true}], "snippet_links": [{"key": "commencement-of-the", "type": "clause", "offset": [5, 24]}, {"key": "phase-iii-trial", "type": "definition", "offset": [31, 46]}, {"key": "in-the-united-states", "type": "clause", "offset": [47, 67]}, {"key": "clinical-candidate", "type": "definition", "offset": [123, 141]}, {"key": "licensed-patents", "type": "clause", "offset": [160, 176]}, {"key": "to-licensor", "type": "clause", "offset": [246, 257]}, {"key": "sum-of", "type": "clause", "offset": [262, 268]}, {"key": "in-cash", "type": "definition", "offset": [329, 336]}, {"key": "piggyback-registration-rights", "type": "clause", "offset": [366, 395]}, {"key": "commencement-of-phase-iii", "type": "definition", "offset": [411, 436]}, {"key": "in-the-event", "type": "clause", "offset": [751, 763]}, {"key": "a-phase", "type": "definition", "offset": [784, 791]}, {"key": "clinical-trial", "type": "clause", "offset": [799, 813]}, {"key": "the-payment", "type": "clause", "offset": [906, 917]}, {"key": "pivotal-study", "type": "definition", "offset": [982, 995]}, {"key": "safety-and-efficacy", "type": "clause", "offset": [1068, 1087]}, {"key": "patient-population", "type": "definition", "offset": [1103, 1121]}, {"key": "basis-of", "type": "clause", "offset": [1172, 1180]}, {"key": "regulatory-approval", "type": "definition", "offset": [1206, 1225]}, {"key": "in-lieu-of", "type": "clause", "offset": [1226, 1236]}, {"key": "appropriate-regulatory-authority", "type": "definition", "offset": [1369, 1401]}], "size": 2, "hash": "c4e7fb41c08b583b993361c053a884e4", "id": 10}], "next_curs": "ClISTGoVc35sYXdpbnNpZGVyY29udHJhY3Rzci4LEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IhJwaGFzZS1paWkjMDAwMDAwMGEMogECZW4YACAA", "clause": {"children": [["\u2587\u2587\u2587\u2587-responsibilities-during-phase", "\u2587\u2587\u2587\u2587 Responsibilities During Phase"], ["phase-iii-closing", "Phase III Closing"], ["time-limit-for-the-phase-iii-closing-and-automatic-termination", "Time Limit for the Phase III Closing and Automatic Termination"], ["requirement-of-cdas-approval", "Requirement of CDA\u2019s Approval"], ["cda-lease-revenue-bonds-phase-iii", "CDA Lease Revenue Bonds-Phase III"]], "title": "Phase III", "size": 77, "parents": [["primary-function-of-the-program-manager", "Primary Function of the Program Manager"], ["entire-contract", "ENTIRE CONTRACT"], ["basic-information-and-definitions", "Basic Information and Definitions"], ["redeployment-of-forces", "Redeployment of Forces"], ["the-project", "The Project"]], "id": "phase-iii", "related": [["phase-ii", "Phase II", "Phase II"], ["phase-2", "Phase 2", "Phase 2"], ["phase-i", "Phase I", "Phase I"], ["phase", "PHASE", "PHASE"], ["development-phase", "Development Phase", "Development Phase"]], "related_snippets": [], "updated": "2025-07-07T12:37:48+00:00"}, "json": true, "cursor": ""}}